JP2019514426A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514426A5
JP2019514426A5 JP2019508165A JP2019508165A JP2019514426A5 JP 2019514426 A5 JP2019514426 A5 JP 2019514426A5 JP 2019508165 A JP2019508165 A JP 2019508165A JP 2019508165 A JP2019508165 A JP 2019508165A JP 2019514426 A5 JP2019514426 A5 JP 2019514426A5
Authority
JP
Japan
Prior art keywords
oligomeric compound
antisense oligomeric
seq
antisense
cpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019508165A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042255B2 (ja
JP2019514426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030174 external-priority patent/WO2017190041A1/en
Publication of JP2019514426A publication Critical patent/JP2019514426A/ja
Publication of JP2019514426A5 publication Critical patent/JP2019514426A5/ja
Priority to JP2022000125A priority Critical patent/JP2022046725A/ja
Application granted granted Critical
Publication of JP7042255B2 publication Critical patent/JP7042255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019508165A 2016-04-29 2017-04-28 ヒトlmnaを標的にするオリゴヌクレオチド類縁体 Active JP7042255B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000125A JP2022046725A (ja) 2016-04-29 2022-01-04 ヒトlmnaを標的にするオリゴヌクレオチド類縁体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330027P 2016-04-29 2016-04-29
US62/330,027 2016-04-29
PCT/US2017/030174 WO2017190041A1 (en) 2016-04-29 2017-04-28 Oligonucleotide analogues targeting human lmna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000125A Division JP2022046725A (ja) 2016-04-29 2022-01-04 ヒトlmnaを標的にするオリゴヌクレオチド類縁体

Publications (3)

Publication Number Publication Date
JP2019514426A JP2019514426A (ja) 2019-06-06
JP2019514426A5 true JP2019514426A5 (US07794700-20100914-C00152.png) 2020-05-21
JP7042255B2 JP7042255B2 (ja) 2022-03-25

Family

ID=59285320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508165A Active JP7042255B2 (ja) 2016-04-29 2017-04-28 ヒトlmnaを標的にするオリゴヌクレオチド類縁体
JP2022000125A Pending JP2022046725A (ja) 2016-04-29 2022-01-04 ヒトlmnaを標的にするオリゴヌクレオチド類縁体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022000125A Pending JP2022046725A (ja) 2016-04-29 2022-01-04 ヒトlmnaを標的にするオリゴヌクレオチド類縁体

Country Status (15)

Country Link
US (2) US10822608B2 (US07794700-20100914-C00152.png)
EP (1) EP3449000A1 (US07794700-20100914-C00152.png)
JP (2) JP7042255B2 (US07794700-20100914-C00152.png)
KR (1) KR102329187B1 (US07794700-20100914-C00152.png)
CN (1) CN109477109B (US07794700-20100914-C00152.png)
AU (2) AU2017258642B2 (US07794700-20100914-C00152.png)
BR (1) BR112018072279A2 (US07794700-20100914-C00152.png)
CA (1) CA3022303A1 (US07794700-20100914-C00152.png)
CO (1) CO2018012873A2 (US07794700-20100914-C00152.png)
EA (1) EA201892467A1 (US07794700-20100914-C00152.png)
MA (1) MA45616A (US07794700-20100914-C00152.png)
MX (1) MX2018013157A (US07794700-20100914-C00152.png)
NZ (1) NZ747685A (US07794700-20100914-C00152.png)
SG (1) SG11201809468XA (US07794700-20100914-C00152.png)
WO (1) WO2017190041A1 (US07794700-20100914-C00152.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018072279A2 (pt) * 2016-04-29 2019-02-12 Sarepta Therapeutics, Inc. análogos de oligonucleotídeo tendo como alvo lmna humana
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
KR102639633B1 (ko) * 2016-12-19 2024-02-26 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
TW202020153A (zh) * 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
WO2020051360A1 (en) * 2018-09-05 2020-03-12 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
WO2022098014A1 (ko) * 2020-11-03 2022-05-12 한국생명공학연구원 유전자 교정을 이용한 조로증 및 자연노화의 예방 또는 치료용 조성물
WO2024097822A1 (en) * 2022-11-02 2024-05-10 Sarepta Therapeutics, Inc. Formulation of an antisense oligomer conjugate

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
EP1242052A4 (en) 1999-12-29 2003-07-02 A James Mixson HISTIDIN COPOLYMER AND METHODS OF USE THEREOF
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
WO2004097017A2 (en) 2003-04-29 2004-11-11 Avi Biopharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
SI2735568T1 (en) 2006-05-10 2018-01-31 Sarepta Therapeutics, Inc. Analogues of the oligonucleotide, with cationic links between subunits
JP2010503707A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
AU2008271050B2 (en) 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
EP2167135A2 (en) 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Wave Life Sciences Japan リン原子修飾核酸の合成方法
CN102625840A (zh) 2009-04-10 2012-08-01 肌肉学研究协会 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
ES2816898T3 (es) * 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
NZ603606A (en) * 2010-05-28 2015-06-26 Sarepta Therapeutics Inc Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
JP5653160B2 (ja) 2010-10-15 2015-01-14 ダンロップスポーツ株式会社 ゴルフボール
CN103619356B (zh) * 2011-05-05 2017-09-12 萨勒普塔医疗公司 肽寡核苷酸缀合物
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9302014B2 (en) 2011-08-30 2016-04-05 Medical Research Council Cell-penetrating peptides having a central hydrophobic domain
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
LT2788487T (lt) * 2011-12-08 2018-09-10 Sarepta Therapeutics, Inc. Oligonukleotido analogai, nukreipti į žmogaus lmna
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
DE102012101676A1 (de) 2012-02-29 2013-08-29 Klaus-Dieter Rösler Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
AU2014253960B2 (en) * 2013-04-16 2020-06-18 Memorial Sloan-Kettering Cancer Center Age-modified cells and methods for making age-modified cells
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
CA2948373A1 (en) * 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) * 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
WO2015179743A1 (en) * 2014-05-23 2015-11-26 Genzyme Corporation Library and screening approach for improved cell penetrating peptides
BR112018072279A2 (pt) * 2016-04-29 2019-02-12 Sarepta Therapeutics, Inc. análogos de oligonucleotídeo tendo como alvo lmna humana

Similar Documents

Publication Publication Date Title
JP2019514426A5 (US07794700-20100914-C00152.png)
JP2018509143A5 (US07794700-20100914-C00152.png)
JP2010527913A5 (US07794700-20100914-C00152.png)
JP2016505586A5 (US07794700-20100914-C00152.png)
JP2016153410A5 (US07794700-20100914-C00152.png)
JP2020536091A5 (US07794700-20100914-C00152.png)
MY161450A (en) Double-acylated glp-1 derivatives
JP2020502049A5 (US07794700-20100914-C00152.png)
JP2019521139A5 (US07794700-20100914-C00152.png)
JP2018530560A5 (US07794700-20100914-C00152.png)
JP2016527215A5 (US07794700-20100914-C00152.png)
JP2017538682A5 (US07794700-20100914-C00152.png)
JP2021506973A (ja) がん治療のための1−(ピペリジノカルボニルメチル)−2−オキソピペラジン誘導体
JP2020503009A5 (US07794700-20100914-C00152.png)
JP2009544660A5 (US07794700-20100914-C00152.png)
JP2009524696A5 (US07794700-20100914-C00152.png)
JP2016533761A5 (US07794700-20100914-C00152.png)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2013505946A5 (US07794700-20100914-C00152.png)
JP2010505741A5 (US07794700-20100914-C00152.png)
JP2020514299A5 (US07794700-20100914-C00152.png)
EP2573110A3 (en) Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
JP2020500916A5 (US07794700-20100914-C00152.png)
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
RU2019110966A (ru) Антисмысловые олигонуклеотиды против scn9a